All Publications

• JAMA 2010 October (304) 1812-1820

• Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

• Roock WD, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Cutsem EV, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S

• View Article

• Science 2010 September (273) 1386-9.

• Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide.

• Cole-Strauss A, Yoon K, Xiang Y, Byrne BC, Rice MC, Gryn J, Holloman WK, Kmiec EB.

• View Article

• Nucleic Acids Res. 2010 September (36) e127

• Epitope tagging of endogenous genes in diverse human cell lines.

• Kim JS, Bonifant C, Bunz F, Lane WS, Waldman T.

• View Article

• AACR 2010 September (Poster Session)

• Mutant PIK3CA increases the expression of individual tubulin isoforms and promotes resistance to anti-mitotic chemotherapy drugs

• Genentech

• View Article

• Impact of the new biology: From genomics to personalized medicine

• Darrin M Disley

• View Article

• Oncogene 2010 August (25) 2048-59

• CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45.

• Dang LH, Chen F, Knock SA, Huang EH, Feng J, Appelman HD, Dang DT.

• View Article

• Cancer Res.  2010 August (66) 6018-24

• Haploinsufficiency of RAD51B causes centrosome fragmentation and aneuploidy in human cells.

• Date O, Katsura M, Ishida M, Yoshihara T, Kinomura A, Sueda T, Miyagawa K.

• View Article

• Oncogene 2010 August (25) 2264-72

• CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48.

• Dang LH, Chen F, Ying C, Chun SY, Knock SA, Appelman HD, Dang DT.

• View Article

• Cancer Res. 2010 August (65) 9485-94

• Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells.

• Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH.

• View Article

• Cell 2010 August (106) 287-96

• Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin.

• Dhar SK, Yoshida K, Machida Y, Khaira P, Chaudhuri B, Wohlschlegel JA, Leffak M, Yates J, Dutta A.

• View Article

• J Clin Invest.  2010 August (120) 2858-66

• Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

• Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A.

• View Article

• Clin Cancer Res.  2010 July (16) 3670-83

• Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

• O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR.

• View Article

• Nature 2010 May (464) 431-5

• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

• Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

• View Article

• Molecular Therapy 2010 May (18) 983-986

• Frequent Endonuclease Cleavage at Off-target Locations In Vivo

• Lisa M Petek, David W Russell and Daniel G Miller

• View Article

• Oncogene 2010 April (29) 2337-45

• Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.

• Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH.

• View Article

• AACR 2010 April (Poster Session)

• Endogenous expression of oncogenic PI3K mutation leads to accumulation of anti-apoptotic proteins at mitochondria

• Mitologics Ltd.

• View Article

• AACR 2010 April (Poster Session)

• The use of X-MAN isogenic cell lines to define PI3-kinase inhibitor activity profiles

• Hypoxium Ltd.

• View Article

• Nat Rev Cancer  2010 April (10) 241-53

• Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

• Sharma SV, Haber DA, Settleman J.

• View Article

• PLoS One.  2010 March (5) e9924

• Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.

• Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M, Péchoux C, Rustin P, Jacotot E, Borgne-Sanchez A.

• View Article

• J Clin Oncol. 2010 March (28) 1181-9

• Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

• Bardelli A, Siena S.

• View Article

• Proc Natl Acad Sci. 2010 March (104) 4383-8

• Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.

• Burkard ME, Randall CL, Larochelle S, Zhang C, Shokat KM, Fisher RP, Jallepalli PV.

• View Article

• PLoS Genet. 2010 February (6) e1000855

• Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells.

• Fattah F, Lee EH, Weisensel N, Wang Y, Lichter N, Hendrickson EA.

• View Article

• Proc Natl Acad Sci U S A.  2010 February (107) 2598-603

• Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.

• Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N.

• View Article

• Cell  2010 January (140) 209-21

• Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

• Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.

• View Article